scholarly journals High-resolution Ultrasound-assisted Assessment of Preliminary Short-term Safety Outcomes of an Implant-based Augmentation Mammaplasty using a Bioengineered, Cell-friendly, Smooth-surface Device in Korean Women

2021 ◽  
Author(s):  
Sangdal Lee ◽  
Jeong Pil Jeong ◽  
Jung Youp Sung ◽  
Woo Sik Choi ◽  
Dong Seung Moon ◽  
...  
Keyword(s):  
Postoperative Complications ◽  
Large Scale ◽  
Breast Implant ◽  
Capsular Contracture ◽  
Augmentation Mammaplasty ◽  
Korean Women ◽  
Short Term ◽  
Fifth Generation ◽  
Body Sensation ◽  
Safety Outcomes

Abstract Background The Motiva Ergonomix™ Round SilkSurface (Establishment Labs Holdings Inc., Alajuela, Costa Rica) is one the representative brands of the fifth-generation of a silicone gel-filled breast implant with a microtextured surface. Objectives In this study, we describe preliminary short-term safety outcomes of an implant-based augmentation mammaplasty using the Motiva Ergonomix™ Round SilkSurface in Korean women. Methods We performed a retrospective analysis of medical records in a total of 69 women (n=69) receiving an implant-based augmentation mammaplasty using the Motiva Ergonomix™ Round SilkSurface between September 26, 2017 and December 31, 2020. We analyzed incidences of postoperative complications. Results A total of 6 cases (8.7%) of postoperative complications occurred; these include 2 cases (2.9%) of early seroma, 1 case (1.4%) of capsular contracture, 2 cases (2.9%) of alterations in the shape and 1 case (1.4%) of foreign body sensation. Time-to-events were estimated at 266.81±273.17 days. Conclusions We describe our preliminary short-term safety outcomes of an implant-based augmentation mammaplasty using the Motiva Ergonomix TM Round SilkSurface in Korean women. But this deserves further large-scale studies with long periods of follow-up.

scholarly journals A Preliminary Retrospective Study to Assess the Short-Term Safety of Traditional Smooth or Microtextured Silicone Gel-Filled Breast Implants in Korea

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1370
Author(s):  
Sanghyuk Han ◽  
Robert Kim ◽  
Tae Seob Kim ◽  
Jung Heum Park ◽  
Seung Soo Kim ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Postoperative Complications ◽  
Subgroup Analysis ◽  
Safety Profile ◽  
Breast Implant ◽  
Breast Implants ◽  
Augmentation Mammaplasty ◽  
Korean Women ◽  
Short Term ◽  
Silicone Gel

Background and objectives We conducted this preliminary retrospective study to assess the short-term safety of silicone gel-filled breast implants (SGBIs) that are commercially available in Korean women. Materials and methods The current retrospective, observational study was conducted in a total of 2612 patients (n =2612) who underwent augmentation mammaplasty using breast implants at our hospitals between 1 January, 2017 and 31 August 2021. Results Overall, there were a total of 248 cases (9.49%) of postoperative complications; these include 112 cases of early seroma, 52 cases of shape deformation, 32 cases of CC, 12 cases of early hematoma, 12 cases of rupture, 12 cases of infection, 12 cases of stretch deformities with skin excess and 4 cases of rippling. Overall complication-free survival of the breast implant was estimated at 1564.32 ± 75.52 days (95% CI 1416.39–1712.32). Then, the Motiva Ergonomix™SilkSurface showed the longest survival (1528.00 ± 157.92 days [95% CI 1218.48–1837.56]), followed by the BellaGelÒSmoothFine (1458.4 ± 65.76 days [95% CI 1329.56–1587.28]), the SebbinÒ Sublimity (1322.00 ± 51.20 days [95% CI 1221.64–1422.32]), the BellaGelÒ Smooth (1138.72 ± 161.28 days [95% CI 822.6–1454.84), the MentorÒ MemoryGel™ Xtra (698.4 ± 52.64 days [95% CI 595.28–801.52]) and the NatrelleÒ INSPIRA™ (380.00 ± 170.88 days [95% CI 45.04–714.96]) in the decreasing order. On subgroup analysis, both the Motiva ErgonomixTM and MentorÒ MemoryGel™ Xtra showed no postoperative complications. However, the BellaGelÒSmoothFine, SebbinÒ Sublimity and BellaGelÒ Smooth showed incidences of 8.87%, 4.84% and 1.61%, respectively. A subgroup analysis also showed differences in incidences of postoperative complications between microtextured and smooth breast implants (15.18% vs. 16.67%). Conclusions In conclusion, our results indicate that diverse types of an SGBI are commercially available and their safety profile varies according to the manufacturer. Plastic surgeons should consider the safety profile of each device in selecting the optimal types of the device for Korean women who are in need of an implant-based augmentation mammaplasty. However, this warrants a single-surgeon, single-center studywith long periods of follow-up.

Clinical Experience with the Fifth-Generation of a Breast Implant with a Smooth, Fine Surface from a Korean Manufacturer in Asian Women

2021 ◽  
Author(s):  
Dong Yeon Hwang ◽  
Sang Wha Kim ◽  
Joon Yong Jung
Keyword(s):  
Clinical Experience ◽  
Safety Assessment ◽  
Breast Implant ◽  
Capsular Contracture ◽  
Asian Women ◽  
Hypertrophic Scars ◽  
Fifth Generation ◽  
Skin Excess ◽  
Fine Surface

Background In this study, we describe our clinical experience with the fifth-generation of a breast implant with a smooth, fine surface from a Korean manufacturer (BellaGelÒ SmoothFine; HansBiomed Co. Ltd., Seoul, Korea) in Asian women. Methods We analyzed 223 women (mean age=35.28±9.45 years and mean follow-up period=12.03±2.48 months), comprising 118 bilateral cases and 109 unilateral ones, who received breast augmentation using the BellaGelÒ SmoothFine at our hospital between June 4, 2018 and February 28, 2019. For safety assessment, we analyzed frequencies of postoperative complications and overall survival of the BellaGelÒ SmoothFine. Results Postoperatively, complications (12 cases, 5.38%) include asymmetry (3 cases, 1.35%), hematoma (2 cases, 0.90%), hypertrophic scars (2 cases, 0.90%), wound disruption (2 cases, 0.90%), rippling (1 case, 0.45%), capsular contracture (1 case, 0.45%), stretch deformities with skin excess (1 case, 0.45%). In addition, time-to-events were calculated as 10.94±0.64 months (95% CI 9.69-12.19). Conclusions Here, we describe our clinical experience with the BellaGelÒ SmoothFine. Our results are of significance in that this is the first report about the fifth-generation of a breast implant with a smooth, fine surface from a Korean manufacturer in Asian women.

scholarly journals Short-term Safety of Augmentation Mammaplasty Using the BellaGel Implants in Korean Women

2019 ◽  
Vol 7 (12) ◽  
pp. e2566 ◽  
Author(s):  
Jung Youp Sung ◽  
Jeong Pil Jeong ◽  
Dong Seung Moon ◽  
Min Soo Kim ◽  
Ho Chan Kim ◽  
...  
Keyword(s):  
Augmentation Mammaplasty ◽  
Korean Women ◽  
Short Term

scholarly journals Clinical Experience with the Fifth-Generation of a Breast Implant with a Smooth, Fine Surface from a Korean Manufacturer in Asian Women

2021 ◽  
Author(s):  
Dong Yeon Hwang ◽  
Sang Wha Kim ◽  
Joon Yong Jung
Keyword(s):  
Clinical Experience ◽  
Safety Assessment ◽  
Breast Implant ◽  
Capsular Contracture ◽  
Asian Women ◽  
Hypertrophic Scars ◽  
Fifth Generation ◽  
Skin Excess ◽  
Fine Surface

Background In this study, we describe our clinical experience with the fifth-generation of a breast implant with a smooth, fine surface from a Korean manufacturer (BellaGelÒ SmoothFine; HansBiomed Co. Ltd., Seoul, Korea) in Asian women. Methods We analyzed 223 women (mean age=35.28±9.45 years and mean follow-up period=12.03±2.48 months), comprising 118 bilateral cases and 109 unilateral ones, who received breast augmentation using the BellaGelÒ SmoothFine at our hospital between June 4, 2018 and February 28, 2019. For safety assessment, we analyzed frequencies of postoperative complications and overall survival of the BellaGelÒ SmoothFine. Results Postoperatively, complications (12 cases, 5.38%) include asymmetry (3 cases, 1.35%), hematoma (2 cases, 0.90%), hypertrophic scars (2 cases, 0.90%), wound disruption (2 cases, 0.90%), rippling (1 case, 0.45%), capsular contracture (1 case, 0.45%), stretch deformities with skin excess (1 case, 0.45%). In addition, time-to-events were calculated as 10.94±0.64 months (95% CI 9.69-12.19) and the survival rate reached 0.290±0.168 (95% CI 0.094-0.901) at 12 months postoperatively. Conclusions Here, we describe our clinical experience with the BellaGelÒ SmoothFine. Our results are of significance in that this is the first report about the fifth-generation of a breast implant with a smooth, fine surface from a Korean manufacturer in Asian women.

scholarly journals A multi-center, retrospective, preliminary observational study to assess the safety of BellaGel® after augmentation mammaplasty

2020 ◽  
Vol 43 (5) ◽  
pp. 577-582
Author(s):  
Moon Seop Choi ◽  
Jae Hoon Chang ◽  
Chul Hwan Seul
Keyword(s):  
Plastic Surgery ◽  
Breast Implant ◽  
Capsular Contracture ◽  
Augmentation Mammaplasty ◽  
The Body ◽  
Consecutive Series ◽  
Level Of Evidence ◽  
Kaplan Meier ◽  
Clinical Series ◽  
Surgery Center

Abstract Background BellaGel® is the only cohesive silicone gel-filled breast implant from a Korean manufacturer, and it was first developed in 2005. It was approved by the CE in 2008, thus becoming the first Asian breast implant available in the EU. We conducted this study to assess the safety of BellaGel® in patients receiving augmentation mammaplasty. Methods We evaluated a consecutive series of 239 patients (478 breasts) who received esthetic augmentation mammaplasty using the BellaGel® (round smooth, round textured, round nanotextured, and anatomical textured types of implant) (HansBiomed Co. Ltd., Seoul, Korea) at three clinics in Korea (JW Plastic Surgery Center, BS The Body Plastic Surgery Clinic and Grace Plastic Surgery Clinic) during a period from December 1, 2015 to January 31, 2018. Results A total of 239 patients with a mean age of 33.1 ± 8.5 years old were followed up during a mean period of 399.58 ± 232.71 days, where there were no cases of capsular contracture in our clinical series of the patients. Other complications include one case (0.4%) of seroma, three cases (1.3%) of hematoma, and one case (0.4%) of infection. Moreover, there were no significant differences in the cumulative incidences of complications between the four types of the BellaGel® (χ2 = 2.322, df = 3, P = 0.508). Furthermore, the cumulative Kaplan-Meier survival rate was estimated at 0.979 (95% CI 0.961–0.997). Conclusions Our results indicate that the BellaGel® is such a safe breast implant that surgeons might consider using it for esthetic augmentation mammaplasty. Level of evidence: Level III, risk/prognostic study.

scholarly journals An Ultrasound-Assisted Approach to an Early Detection of Complications of an Implant-Based Augmentation Mammaplasty using the BellaGel® SmoothFine: Preliminary 3-year Clinical Experience

2021 ◽  
Vol 7 (2) ◽  
Author(s):  
Song KY ◽  
Sung JY ◽  
Choi WS ◽  
Lim HG ◽  
Kim JH
Keyword(s):  
Breast Implant ◽  
Breast Implants ◽  
Augmentation Mammaplasty ◽  
Evidence Based ◽  
Korean Women ◽  
Background Selection ◽  
Essential Factor ◽  
Patients Satisfaction ◽  
Ultrasound Assisted ◽  
Selection Of

Background: Selection of optimal types of breast implants is an essential factor that determines the degree of patients’ satisfaction with outcomes of augmentation mammaplasty, for which an evidence-based approach to it is mandatory. Several studies have supported the safety of the BellaGel® SmoothFine (HansBiomed Co. Ltd., Seoul, Korea), a silicone gel-filled breast implant from a Korean manufacturer. But such studies have been conducted in a manufacturer-sponsored setting. We therefore conducted this non-manufacturer-sponsored, retrospective study to assess its 3-year safety outcomes in Korean women.

scholarly journals BattleNet: Capturing Advantageous Battlefield in RTS Games (Student Abstract)

2020 ◽  
Vol 34 (10) ◽  
pp. 13849-13850
Author(s):  
Donghyeon Lee ◽  
Man-Je Kim ◽  
Chang Wook Ahn
Keyword(s):  
Artificial Intelligence ◽  
Decision Making ◽  
Real Time ◽  
Large Scale ◽  
Outcome Predictor ◽  
Short Term ◽  
Rts Game

In a real-time strategy (RTS) game, StarCraft II, players need to know the consequences before making a decision in combat. We propose a combat outcome predictor which utilizes terrain information as well as squad information. For training the model, we generated a StarCraft II combat dataset by simulating diverse and large-scale combat situations. The overall accuracy of our model was 89.7%. Our predictor can be integrated into the artificial intelligence agent for RTS games as a short-term decision-making module.

scholarly journals Blastocyst formation, embryo transfer and breed comparison in the first reported large scale cloning of camels

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
P. O. Olsson ◽  
A. H. Tinson ◽  
N. Al Shamsi ◽  
K. S. Kuhad ◽  
R. Singh ◽  
...  
Keyword(s):  
Embryo Transfer ◽  
Nuclear Transfer ◽  
Large Scale ◽  
Donor Cell ◽  
Blastocyst Formation ◽  
Short Term ◽  
Embryo Formation ◽  
Large Expansion ◽  
Breed Differences ◽  
Breed Comparison

AbstractCloning, through somatic cell nuclear transfer (SCNT), has the potential for a large expansion of genetically favorable traits in a population in a relatively short term. In the present study we aimed to produce multiple cloned camels from racing, show and dairy exemplars. We compared several parameters including oocyte source, donor cell and breed differences, transfer methods, embryo formation and pregnancy rates and maintenance following SCNT. We successfully achieved 47 pregnancies, 28 births and 19 cloned offspring who are at present healthy and have developed normally. Here we report cloned camels from surgical embryo transfer and correlate blastocyst formation rates with the ability to achieve pregnancies. We found no difference in the parameters affecting production of clones by camel breed, and show clear differences on oocyte source in cloning outcomes. Taken together we demonstrate that large scale cloning of camels is possible and that further improvements can be achieved.

How to increase customer repeated bookings in the short-term room rental market? A large-scale granular data investigation

2021 ◽  
Vol 143 ◽  
pp. 113495
Author(s):  
Jiang Wu ◽  
Jingxuan Cai ◽  
Xin (Robert) Luo ◽  
Jose Benitez
Keyword(s):  
Large Scale ◽  
Short Term ◽  
Rental Market ◽  
Data Investigation

scholarly journals The Role of Risk Preferences in Responses to Messaging About COVID-19 Vaccine Take-Up

2021 ◽  
pp. 194855062199962
Author(s):  
Jennifer S. Trueblood ◽  
Abigail B. Sussman ◽  
Daniel O’Leary
Keyword(s):  
Large Scale ◽  
Risk Preferences ◽  
Herd Immunity ◽  
Disease Spread ◽  
Short Term ◽  
Policy Makers ◽  
Health Crisis ◽  
Flu Vaccine ◽  
Nationally Representative

Development of an effective COVID-19 vaccine is widely considered as one of the best paths to ending the current health crisis. While the ability to distribute a vaccine in the short-term remains uncertain, the availability of a vaccine alone will not be sufficient to stop disease spread. Instead, policy makers will need to overcome the additional hurdle of rapid widespread adoption. In a large-scale nationally representative survey ( N = 34,200), the current work identifies monetary risk preferences as a correlate of take-up of an anticipated COVID-19 vaccine. A complementary experiment ( N = 1,003) leverages this insight to create effective messaging encouraging vaccine take-up. Individual differences in risk preferences moderate responses to messaging that provides benchmarks for vaccine efficacy (by comparing it to the flu vaccine), while messaging that describes pro-social benefits of vaccination (specifically herd immunity) speeds vaccine take-up irrespective of risk preferences. Findings suggest that policy makers should consider risk preferences when targeting vaccine-related communications.

Sign in / Sign up

Export Citation Format

Share Document